Despite the approval of several targeted therapeutic agents for the treatment of cancer patients, colorectal cancer is a major health problem. It is essential to discover additional and colorectal cancer-specific therapeutic targets. Moreover, for the past few decades, we and others have been working on the development of more effective and less toxic therapeutic interventions for patients with colorectal cancer. One promising area is targeting HER family proteins, which help cancer cells grow. This review article highlights advances in the development of various drugs that block HER proteins and other proteins that are at different stages of clinical development, and the therapeutic potential of such drugs when used in combination to overcome current challenges, such as poor response or no response. The goal is to find treatments that are more effective and have fewer side effects, ultimately improving the quality of life of patients receiving treatment for colorectal cancer.
Please find the link to the full review below
